TriNebula Cell Tech Overview
- Year Founded
-
2026
- Status
-
Private
- Latest Deal Type
-
Joint Venture
- Financing Rounds
-
1
TriNebula Cell Tech General Information
Description
Provider of marketing services intended to promote human induced pluripotent stem cell-derived products for drug discovery. The company utilizes human induced pluripotent stem cell differentiation, safety evaluation platforms, non-clinical testing integration, quality management systems, market feedback loops, and regulatory trend monitoring, providing pharmaceutical companies with alternatives to animal testing for more accurate drug safety screening.
Contact Information
Corporate Office
- 1-1-1 Ichigaya Kagacho
- Shinjuku ku, Tokyo
- Japan
Corporate Office
- 1-1-1 Ichigaya Kagacho
- Shinjuku ku, Tokyo
- Japan
TriNebula Cell Tech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
TriNebula Cell Tech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
TriNebula Cell Tech FAQs
-
When was TriNebula Cell Tech founded?
TriNebula Cell Tech was founded in 2026.
-
Where is TriNebula Cell Tech headquartered?
TriNebula Cell Tech is headquartered in Shinjuku ku, Japan.
-
What industry is TriNebula Cell Tech in?
TriNebula Cell Tech’s primary industry is Media and Information Services (B2B).
-
Is TriNebula Cell Tech a private or public company?
TriNebula Cell Tech is a Private company.
-
What is TriNebula Cell Tech’s current revenue?
The current revenue for TriNebula Cell Tech is .
-
Who are TriNebula Cell Tech’s investors?
CMIC Holdings, Dai Nippon Printing, and Nexel have invested in TriNebula Cell Tech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process